Fussgoenheim, Germany

Fritz Binnig

This inventor holds 4 USPTO granted patents. Top assignee: Basf Aktiengesellschaft. Active years: 1980-1990.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 1980-1990

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Fritz Binnig

Introduction

Fritz Binnig is a notable inventor hailing from Fussgoenheim, Germany. He has made significant contributions to the field of chemistry, particularly in the development of antiarrhythmic agents. With a total of 4 patents to his name, Binnig's work has had a lasting impact on medical science.

Latest Patents

Binnig's latest patents include innovative compounds such as bispidine derivatives, which serve as class III antiarrhythmic agents. These compounds are characterized by their unique chemical structures, where R, R¹, and R³ can vary, and they exhibit properties that are beneficial in treating arrhythmias. Another significant patent involves bispidine derivatives that possess antiarrhythmic properties, showcasing their potential as effective therapeutic agents.

Career Highlights

Throughout his career, Binnig has been associated with BASF Aktiengesellschaft, a leading chemical company. His work has focused on the synthesis and application of novel compounds that can improve heart health. His research has contributed to advancements in pharmacology and therapeutic treatments.

Collaborations

Binnig has collaborated with esteemed colleagues such as Manfred Raschack and Claus D. Mueller. These partnerships have fostered a collaborative environment that has led to innovative discoveries in the field of chemistry.

Conclusion

Fritz Binnig's contributions to the field of chemistry and his innovative patents have made a significant impact on medical science. His work continues to inspire future research and development in antiarrhythmic therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…